Viatris Inc. is a global healthcare company formed on November 16, 2020, through the combination of Mylan N.V. and Pfizer’s Upjohn Business in a Reverse Morris Trust transaction [10-K, p. 10]. Headquartered in Canonsburg, Pennsylvania, with global centers in Pittsburgh, Shanghai, and Hyderabad, Viatris operates in more than 165 countries and territories with over 30,000 employees [10-K, p. 7]. Its portfolio spans generics (including complex products), globally recognized iconic brands (e.g., Lipitor, Norvasc, EpiPen, Lyrica, Viagra), and an expanding portfolio of innovative medicines [10-K, p. 7]. The company reports through four segments: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets [10-K, p. 17]. Viatris was added to the S&P 500 Index on April 23, 2004, and has a fiscal year ending December [Dashboard, Company Information].
2. Executive Summary
Viatris is a company in transition. The FY2025 results reflect the heavy burden of a $2.94 billion non-cash goodwill impairment** recorded in Q1 2025, which drove a full-year net loss of **$3.51 billion [10-K, p. 61]. However, the underlying operational picture is stabilizing. The 9M 2026 results show total revenues of $11.02 billion** (+4% YoY) and a dramatic swing to a **$188.1 million operating profit from an operating loss of $2.47 billion in 9M 2025 (which was impaired by the goodwill charge) [10-Q, p. 6].
The market has taken notice. As of November 12, 2026, VTRS trades at **$20.67**, representing a **65.89% period return** from the January 5, 2026 low of $12.19 [Dashboard, Market Snapshot]. The stock’s 32.19% annualized volatility reflects both the operational turnaround narrative and the persistent risk overhang from litigation and manufacturing compliance. The dashboard’s Composite Score of 25.1 (Valuation: 62.5, Quality: 12.8, Growth: 0.0) captures the tension precisely: the stock is inexpensive on forward metrics (Forward PE 7.58, EV/EBITDA 8.16), but reported GAAP earnings remain deeply negative, and the growth score reflects the collapse in annual EPS from -$0.53 in FY2024 to -$3.00 in FY2025 [Dashboard, Composite Scores; Growth Metrics].
The key tension for new investors is between persistent GAAP losses (driven by amortization, impairments, and a high tax burden) and resilient cash generation. Viatris generated $1.67 billion in operating cash flow** in 9M 2026 [10-Q, p. 11]. The company is executing a **$700–$850 million restructuring program** (EWSR) targeting $600–$700 million in annual savings by 2028 [10-K, p. 9]. It is also pivoting toward higher-margin innovative and complex products via bolt-on M&A (e.g., the pending **$1.65 billion Pacira acquisition) [10-Q, p. 15]. However, significant risks remain: manufacturing compliance issues at the Indore and Nashik facilities in India, massive litigation overhangs (generic drug pricing, opioids), and a high leverage ratio that constrains financial flexibility. The dashboard’s sector comparison underscores the quality gap: Viatris’s ROE of -4.21% versus the Health Care sector average of 19.52%, and ROIC of -10.91% versus 19.51%, highlight how far the company’s returns lag its peers [Dashboard, Sector Comparison].
3. Comparative Financial Statements & Ratio Analysis
A. Income Statement (9M 2026 vs. 9M 2025)
| Item (USD M) | 9M 2026 | 9M 2025 | Change % | Source (10-Q) |
|---|---|---|---|---|
| Total Revenues | 11,023.3 | 10,596.3 | +4.0% | p. 6 |
| Cost of Sales | 6,971.6 | 6,730.7 | +3.6% | p. 6 |
| Gross Profit | 4,051.7 | 3,865.6 | +4.8% | p. 6 |
| R&D Expense | 728.6 | 691.2 | +5.4% | p. 6 |
| SG&A Expense | 3,014.1 | 2,763.4 | +9.1% | p. 6 |
| Impairment of Goodwill | — | 2,936.8 | -100% | p. 6 |
| Litigation Settlements, Net | 115.7 | (65.4) | NM | p. 6 |
| Operating Income (Loss) | 188.1 | (2,470.4) | NM | p. 6 |
| Interest Expense | 353.2 | 351.7 | +0.4% | p. 6 |
| Other Expense, Net | 18.3 | 499.9 | -96.3% | p. 6 |
| Income Tax Provision (Benefit) | 84.3 | (147.2) | NM | p. 6 |
| Net Loss | (267.7) | (3,174.8) | -91.6% | p. 6 |
| Diluted EPS | $(0.23) | $(2.70) | NM | p. 6 |
Key Takeaway: The YoY improvement in operating income and net loss is almost entirely due to the absence of the prior-year goodwill impairment. Revenue growth was driven by Greater China (+19%) and new product launches, partially offset by supply constraints in Europe and Emerging Markets [10-Q, p. 60]. The dashboard’s Operating Margin of 11.49% (with a trend arrow of ▲ 18.62%) reflects this sharp recovery from the impairment-distorted prior period [Dashboard, Profitability & Margins].
B. Balance Sheet (September 30, 2026 vs. December 31, 2025)
| Item (USD M) | Sep 30, 2026 | Dec 31, 2025 | Change % | Source (10-Q) |
|---|---|---|---|---|
| Cash & Equivalents | 1,789.2 | 1,322.4 | +35.3% | p. 8 |
| Accounts Receivable, Net | 3,121.2 | 3,031.3 | +3.0% | p. 8 |
| Inventories | 3,829.2 | 3,999.2 | -4.3% | p. 8 |
| Total Current Assets | 10,297.8 | 9,789.2 | +5.2% | p. 8 |
| Intangible Assets, Net | 13,079.5 | 15,102.1 | -13.4% | p. 8 |
| Goodwill | 6,620.0 | 6,754.7 | -2.0% | p. 8 |
| Total Assets | 34,682.6 | 37,193.1 | -6.7% | p. 8 |
| Accounts Payable | 1,653.3 | 1,754.1 | -5.7% | p. 8 |
| Current Portion of LT Debt | 1,727.5 | 1,933.3 | -10.6% | p. 8 |
| Total Current Liabilities | 6,636.5 | 7,094.3 | -6.5% | p. 8 |
| Long-Term Debt | 11,587.5 | 12,480.6 | -7.2% | p. 8 |
| Total Liabilities | 20,997.1 | 22,481.8 | -6.6% | p. 8 |
| Total Equity | 13,685.5 | 14,711.3 | -7.0% | p. 8 |
Key Takeaway: The balance sheet is shrinking primarily due to the amortization of intangibles and debt repayment. The $1.67 billion reduction in total debt (current + long-term) is a positive signal for deleveraging [10-Q, p. 8]. The dashboard’s PB Ratio of 1.73, a 72.43% discount to the Health Care sector average of 6.28, reflects the market’s skepticism about the carrying value of these assets [Dashboard, Sector Comparison].
C. Cash Flow Statement (9M 2026 vs. 9M 2025)
| Item (USD M) | 9M 2026 | 9M 2025 | Change | Source (10-Q) |
|---|---|---|---|---|
| Operating Cash Flow | 1,669.5 | 1,500.1 | +169.4 | p. 11 |
| Capital Expenditures | (178.4) | (182.3) | +3.9 | p. 11 |
| Proceeds from Sale of Investments (Biocon) | 779.8 | — | +779.8 | p. 11 |
| Investing Cash Flow | 518.1 | (216.5) | +734.6 | p. 11 |
| Debt Repayment (Net) | (922.2) | — | -922.2 | p. 11 |
| Share Repurchases | (300.0) | (415.4) | +115.4 | p. 11 |
| Dividends Paid | (416.9) | (423.0) | +6.1 | p. 11 |
| Financing Cash Flow | (1,736.2) | (1,057.5) | -678.7 | p. 11 |
| Net Change in Cash | 444.7 | 267.4 | +177.3 | p. 11 |
Key Takeaway: Operating cash flow remains robust. The company used the $780 million proceeds from the Biocon equity sale to pay down debt and fund dividends/repurchases [10-Q, p. 11].
D. Ratio Analysis (9M 2026)
Industry benchmarks are approximate, derived from general U.S. pharmaceutical/generic sector norms (S&P Capital IQ / Damodaran data) and the dashboard’s Health Care sector comparison [Dashboard].
| Ratio Category | Ratio | Viatris (9M 2026) | Calculation / Source | Approx. U.S. Pharma Ind. Avg. | Assessment |
|---|---|---|---|---|---|
| Liquidity | Current Ratio | 1.55x | 10,297.8 / 6,636.5 [10-Q, p. 8] | ~1.8x | Adequate, but below sector |
| Quick Ratio | 0.97x | (10,297.8 – 3,829.2) / 6,636.5 | ~1.3x | Relies on inventory; tight | |
| Leverage | Debt-to-Equity | 0.97x | 13,315.0 / 13,685.5 [10-Q, p. 8] | ~0.6x | High leverage; key risk |
| Interest Coverage | 1.5x | 188.1 / 353.2 [10-Q, p. 6] | >8x | Weak; EBIT barely covers interest | |
| Profitability | Gross Margin | 36.8% | 4,051.7 / 11,023.3 [10-Q, p. 6] | 49.09% (Health Care sector) [Dashboard] | Below sector |
| Operating Margin | 1.7% | 188.1 / 11,023.3 | 18.03% (Health Care sector) [Dashboard] | Very low due to amortization/SG&A | |
| Net Margin | -2.4% | (267.7) / 11,023.3 | ~10-15% | Negative; GAAP loss | |
| ROE (annualized) | -2.6% | (267.7*4/3) / 13,685.5 | 19.52% (Health Care sector) [Dashboard] | Poor | |
| ROIC | -10.91% | Dashboard | 19.51% (Health Care sector) [Dashboard] | Severely below sector | |
| Efficiency | Inventory Days | 150 days | (3,829.2 / 6,971.6) * 270 | ~120 days | High; risk of obsolescence |
| Receivables Days | 76 days | (3,121.2 / 11,023.3) * 270 | ~60 days | Elevated | |
| Payables Days | 64 days | (1,653.3 / 6,971.6) * 270 | ~90 days | Low; paying suppliers quickly |
4. Opportunities and Threats (Investor Perspective)
Opportunities (from scanning 10-K/10-Q and Dashboard):
- Restructuring Savings: The EWSR program is expected to deliver $600–$700 million in annual savings by 2028, with most improving operating cash flow [10-K, p. 9; 10-Q, p. 54].
- Innovative Pipeline: Positive Phase 3 data for fast-absorbing meloxicam and a low-dose estrogen patch (PDUFA July 30, 2026) could drive higher-margin growth [10-K, p. 8].
- Pacira Acquisition: The $1.65 billion deal brings high-margin, patent-protected U.S. products (EXPAREL, ZILRETTA) that Viatris can leverage its IP expertise to extend [10-Q, p. 15].
- Biocon Exit: The sale of the Biocon stake for ~$780 million in cash removes a volatile equity investment and provides funds for debt reduction [10-Q, p. 28].
- Greater China Momentum: 9M 2026 sales grew 19% YoY, driven by e-commerce and retail channels [10-Q, p. 61].
- Valuation Gap: The dashboard’s Forward PE of 7.58 and EV/EBITDA of 8.16 are well below sector averages, suggesting the market is pricing in significant pessimism that could reverse if execution improves [Dashboard, Valuation Metrics].
Threats:
- Manufacturing Compliance (Indore & Nashik): The Indore facility received an FDA Official Action Indicated (OAI) classification and an import alert affecting 11 products [10-K, p. 14]. The Nashik facility was voluntarily suspended in October 2026, with an expected $100 million revenue hit in Q4 2026 [10-Q, p. 55]. These issues threaten supply continuity and reputation.
- Litigation Overhang: Viatris faces significant litigation, including generic drug pricing MDLs (Clomipramine bellwether damages asserted at ~$350 million, subject to trebling) and opioid settlements [10-Q, p. 44].
- Leverage and Interest Burden: With interest coverage at ~1.5x, any rise in rates or decline in EBITDA could strain the company’s ability to service debt and maintain its dividend [10-K, p. 48].
- Pricing Pressure: Continued VBP (Volume-Based Procurement) in China and tender systems in Europe/emerging markets pressure pricing [10-K, p. 26].
- Quality Score of 12.8: The dashboard’s composite quality metric is alarmingly low, reflecting the sustained negative ROE, ROA, and margins relative to peers [Dashboard, Composite Scores].
5. Audit Objections / Observations Impacting Future Earnings
Critical Audit Matter (CAM) — Goodwill Impairment (Deloitte & Touche LLP):
The auditor identified the goodwill impairment assessment as a critical audit matter due to the significant estimates and assumptions used, particularly the discount rates and terminal growth rates for reporting units with remaining goodwill [10-K, p. 83].
- Observation: The Greater China reporting unit had a fair value only 5.8% above its carrying value as of the April 1, 2026 test [10-K, p. 77]. A 1.0% increase in the discount rate or a 3.5% reduction in terminal growth rate would trigger an impairment [10-K, p. 77].
- Impact: Given the volatility in Chinese markets and the recent strong performance in Greater China, this remains a watch item. Any impairment would be non-cash but would further erode book equity and could impact debt covenants indirectly (though covenants are EBITDA-based).
Internal Control over Financial Reporting (ICFR):
Deloitte issued an unqualified opinion on ICFR as of December 31, 2025 [10-K, p. 85]. However, the 10-Q notes that the company is implementing a new ERP system for entities outside the U.S., which introduces inherent risks to controls during the transition [10-Q, p. 73].
6. Litigation: Current Position and Probable Impact (What-If Analysis)
Generic Drug Pricing MDL (Clomipramine):
- Status: Viatris is a defendant in bellwether cases. Plaintiffs assert damages of ~$350 million in each of the Clomipramine cases, subject to trebling under federal law (direct purchaser) or multipliers under state law (indirect purchaser) [10-Q, p. 44].
- What-If Impact (Worst Case): If Viatris were found liable for the full $350M trebled ($1.05 billion) in the direct case, this would be a material event. However, it is more likely that any settlement or judgment would be shared among multiple defendants. A $200 million** net impact would reduce EPS by approximately **$0.17 (assuming 1.15 billion diluted shares).
Opioid Litigation:
- Status: A nationwide settlement framework is finalized at a maximum of $335 million** over 9 years [10-Q, p. 47]. The company has accrued **$281.3 million as of Sep 30, 2026 [10-Q, p. 47].
- What-If: This is largely provisioned for. The remaining risk is from non-covered cases (e.g., personal injury plaintiffs). An adverse judgment of $100 million** would reduce EPS by ~**$0.09.
Pfizer Indemnification Dispute (Opioids):
- Status: Viatris agreed to pay Pfizer 57% of any losses related to opioid actions since July 29, 2019. In June 2026, Pfizer requested payment; Viatris disagrees [10-Q, p. 41].
- What-If: If Viatris were forced to pay a significant portion of Pfizer’s opioid liabilities (beyond Viatris’s own accruals), this could be a substantial unexpected cash outflow. This is a key tail risk not fully quantifiable from the filing.
7. Related Party Transactions
Pfizer Relationship:
- TSA (Transition Services): The companies have various transition services agreements. TSA income for 9M 2026 was lower YoY [10-Q, p. 63].
- Opioid Cost-Sharing: As noted above, Viatris has a 57% loss-sharing obligation to Pfizer for opioid-related third-party actions [10-Q, p. 41]. This is a significant related-party risk.
- Indemnifications: Viatris generally indemnifies Pfizer for assumed Upjohn legal matters, while Pfizer retains certain competition law matters [10-K, p. 42].
Biocon:
- Equity Sale: The sale of the CCPS and subsequent equity shares to Biocon was a related-party transaction. The loss on remeasurement/sale was $36.0 million in 9M 2026 [10-Q, p. 28].
8. Investment in Other Company Shares
Biocon Limited (India):
- Status: Viatris received $415 million in newly issued Biocon equity shares** in January 2026 as part of the CCPS sale. The shares were subject to a six-month lock-up. Viatris **completed the sale on July 14, 2026**, for pre-tax proceeds of approximately **$380 million [10-Q, p. 28].
- Impact: Viatris no longer holds any equity stake in Biocon. The proceeds were used for general corporate purposes, including debt repayment [10-Q, p. 69].
Mapi Pharma:
- Status: Viatris holds preferred shares in Mapi, but they were fully impaired in 2024 [10-Q, p. 41]. The license agreement for GA Depot was terminated in April 2026 [10-Q, p. 41]. No remaining value.
📊 Latest Equity Research & Market Insights
Apple Inc. (AAPL) — Comprehensive Multi‑Year Equity Research Report
Read Report →Microsoft Corporation (MSFT) — Investment Analysis Report
Read Report →NVIDIA Corporation (NVDA) — Integrated Equity Research Report
Read Report →Berkshire Hathaway (NYSE: BRK-B) — Analytical Equity Research Report
Read Report →✅ S&P 500 Weekly Market Pulse (Oct 5–9, 2026)
Read Pulse →✅ NASDAQ 100 Weekly Market Pulse (Oct 5–9, 2026)
Read Pulse →9. Other Important Issues
Dividend Sustainability: Viatris paid **$416.9 million** in dividends in 9M 2026 [10-Q, p. 11]. With operating cash flow of $1.67 billion and capex of $178 million, the dividend is covered by free cash flow (~$1.49 billion). However, the high debt load and interest expense (annualized ~$470 million) mean the dividend consumes a significant portion of discretionary cash flow. The dashboard’s Dividend Payout data (displayed as a chart in the source dashboard) is not extractable in tabular form here, but the quarterly $0.12 per share payout has been maintained consistently [10-K, p. 55].
Debt Maturity Profile: Viatris has $1.7 billion due in 2027** and **$1.6 billion due in 2028 [10-K, p. 31]. The company successfully refinanced the 2026 notes with new 2033 Euro notes, extending maturities. The focus will remain on deleveraging to reduce interest expense and improve financial flexibility.
Ownership Structure: The dashboard shows institutional ownership of 51.70% among the top 10 institutional holders, with FMR, LLC (8.37%), Blackrock (7.45%), and Vanguard entities (combined ~11.28%) as the largest holders [Dashboard, Shareholding Movement]. This high institutional ownership suggests that the stock’s recent rally may be supported by fundamental conviction rather than retail speculation.
10. 9-Month Performance Summary at a Glance (10-Q)
| Metric | 9M 2026 | 9M 2025 | Change % | Source |
|---|---|---|---|---|
| Revenue | $11,023.3 M | $10,596.3 M | +4.0% | 10-Q p. 6 |
| Gross Profit | $4,051.7 M | $3,865.6 M | +4.8% | 10-Q p. 6 |
| Operating Profit | $188.1 M | $(2,470.4) M | NM | 10-Q p. 6 |
| Net Income (Loss) | $(267.7) M | $(3,174.8) M | -91.6% | 10-Q p. 6 |
| EPS (Basic) | $(0.23) | $(2.70) | NM | 10-Q p. 6 |
| Diluted EPS | $(0.23) | $(2.70) | NM | 10-Q p. 6 |
| NAV per Share | $11.93 | ~$12.20 (Dec 2025) | -2.2% | Calculated (13,685.5 / 1,146.5) |
| Net Cash Flow per Share | $1.46 | $1.27 | +15.0% | (1,669.5 / 1,146.5) |
| Total Assets | $34,682.6 M | $37,193.1 M (Dec 2025) | -6.7% | 10-Q p. 8 |
| Total Equity | $13,685.5 M | $14,711.3 M (Dec 2025) | -7.0% | 10-Q p. 8 |
NAV per Share and Net Cash Flow per Share are calculated using the shares outstanding as of Nov 2, 2026 (1,146,454,729) [10-Q, p. 1].
11. Next Quarter and FY2026 Projections (Bear / Base / Bull)
Consensus data sourced from S&P Global via Stock Analysis and GNG Research; company guidance from Q3 2026 earnings release .
FY2026 Guidance (Company): Revenue ~$14.8 billion (midpoint), Adjusted EPS ~$2.59 (midpoint), Adjusted EBITDA ~$4.5 billion .
Projection Rationale:
- Bear Case: Nashik supply disruption persists longer than expected (~$100M Q4 revenue hit per company guidance [10-Q, p. 55]), Greater China growth decelerates, and litigation accruals spike. GAAP net loss continues due to restructuring charges and high interest expense. Stock retests the October 2026 lows near $14.
- Base Case: Company delivers on low end of revenue guidance ($14.78B consensus ). Nashik impact is contained within guidance. Restructuring savings begin to partially offset inflation. GAAP results approach breakeven but remain slightly negative due to amortization. Stock trades in line with consensus target of $21.
- Bull Case: Nashik remediation accelerates, Greater China momentum sustains, and Pacira acquisition closes smoothly with immediate accretion to adjusted EBITDA. Litigation settlements come in below accruals. GAAP net income turns positive. UBS’s $28 target reflects this optimism .
Important Note on GAAP vs. Adjusted: The FY2026 consensus Adjusted EPS of $2.59 is substantially higher than the GAAP EPS figures projected above. The gap is driven by ~$1.7 billion in annual intangible amortization, restructuring charges, and litigation accruals that are excluded from adjusted figures. New investors should be aware that the company’s “profitability” on an adjusted basis is far stronger than its GAAP results suggest.
12. PDF Reference Page Numbers (Quick Check)
| Section | 10-K Page Ref | 10-Q Page Ref |
|---|---|---|
| Company Overview / Business | pp. 7-22 | pp. 52-56 |
| Risk Factors (Key) | pp. 23-53 | pp. 73-74 |
| Legal Proceedings | pp. 144-152 | pp. 43-50 |
| MD&A | pp. 57-80 | pp. 51-73 |
| Financial Statements (Income) | p. 87 | p. 6 |
| Financial Statements (Balance Sheet) | p. 86 | p. 8 |
| Financial Statements (Cash Flow) | p. 90 | p. 11 |
| Goodwill Impairment / CAM | pp. 83-84, p. 77 | — |
| Debt | pp. 117-119 | pp. 29-31 |
| Related Party (Pfizer Opioid) | p. 42 | p. 41 |
13. Data Sources
- Viatris Inc. FY2025 Form 10-K (filed February 26, 2026): Financial statements, footnotes, risk factors, legal proceedings, audit report.
- Viatris Inc. Q3 2026 Form 10-Q (filed November 5, 2026): Interim financial statements, MD&A, litigation updates, subsequent events.
- Capital Insight BD S&P 500 Stock Analysis Master Dashboard (VTRS, period 2026-01-01 to 2026-11-12): Market snapshot, composite scores, valuation metrics, sector comparison, ownership data.
- Consensus Estimates and Analyst Targets: S&P Global via Stock Analysis (12 analysts, November 2026) ; GNG Research (EPS/revenue consensus) ; Barchart (Q3 2026 earnings and company guidance) ; Twelve Data (revenue estimates) ; UBS and Piper Sandler price targets via Business Insider and Stock Analysis .
- Industry Benchmarks: Damodaran data (NYU Stern) for U.S. pharmaceutical/generic sector averages, supplemented by the Dashboard’s Health Care sector comparison.
14. Disclaimer
This report is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. The analysis is based on the attached FY2025 Form 10-K, Q3 2026 Form 10-Q, the Capital Insight BD dashboard data, and publicly available consensus estimates as cited. Financial figures are unaudited for interim periods and are subject to change. Forward-looking projections are estimates based on available data and are not guarantees of future performance. Investing in securities involves risk, including the possible loss of principal. Readers should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. The author and CapitalinsightBD are not liable for any losses arising from the use of this information.
Md Kollol Hossain
CEO, CapitalinsightBD
info@capitalinsightbd.com
